New Market Study Published: Belgium Pharmaceuticals & Healthcare Report Q1 2013
BMI View: We remain less than optimistic about the short-term growth of the Belgian pharmaceutical market. Through to 2016, the market's value is expected to post a negative compound annual growth rate (CAGR) of -1% in both local currency and US dollar terms, largely on account of cost containment measures and patent expirations. Nevertheless, foreign companies are expected to continue using Belgian production sites for exports, the country also being a popular re-export source.
View full press release